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X-Linked cardioskeletal myopathy, neutropenia and abnormal mitochondria (McKusick 
302060; 3-methylglutaconic aciduria type2; Barth syndrome) represents a rare metabolic 
disorder with a distinct clinical phenotype, reported so far from Europe (Barth et al 1983), 
North-America (Gibson et al 1991; Kelley et al 1991) and Australia (Ad6s et al 1993; 
Christodoulou et al 1994). It has the following clinical and biochemical profile: dilated 
cardiomyopathy; neutropenia due to maturation arrest; neuromuscular weakness; absence 
of cerebral involvement; and diminished statural growth. Clinical biochemical features 
include variable lactic acidaemia and lactic aciduria (Barth et al 1983); increased urinary 
excretion of 3-methylglutaconic acid, 3-methylglutaric a id and 2-ethylhydracrylic a id 
(Kelley et al 1991; Gibson et al 1991); and low serum cholesterol (Kelley et al 1991). 
Linkage analysis assigned the disease todistal Xq28 (Bolhuis et al 1991; Adds et al 1993; 
Christodoulou et al 1994). Previous studies on the respiratory chain in skeletal muscle 
showed impaired oxidative phosphorylation at the level of complexes III and IV (Barth et 
al 1983) and decreased activity of complex IV (Christodoulou et al 1994). Results of 
clinical experiments pertaining to the organic acid abnormality and the low serum 
cholesterol included absent effect of leucine loading on the excretion of 3-methyl- 
glutaconic acid (Kelley et al 1991; Christodoulou etal 1994); normal activities of enzymes 
in the leucine pathway (3-methylglutaconyl-CoA hydratase (EC 4.2.1.18), 3-hydroxy-3- 
methylglutaryl-CoA lyase (EC 4.1.3.4), 3-hydroxy-3-methylglutaryl-CoA reductase); and 
normal in vitro biosynthesis of [14C]cholesterol from [J4C]acetate (Gibson et al 1991). 
By ascertaining respiratory-chain function in cultured fibroblasts we expected to 
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establish whether respiratory-chain abnormalities extend to other tissues beyond striated 
muscle. Furthermore, we wanted to exclude the possibility hat such abnormalities were 
associated with mutated or depleted mitochondrial DNA (mtDNA) by studying the in vitro 
biosynthesis of mitochondrially encoded subunits of the relevant complexes. 
MATERIALS AND METHODS 
Fibroblasts were obtained from two patients from different pedigrees. Patient 1 belonged 
to an earlier described family (Barth et al 1983), patient 2 to a recently discovered new 
family. 
Mitochondrial ATP synthesis was measured in fibroblasts frora exponentially growing 
cultures, permeabilized with low concentrations of digitonin (1/~g/106 cells). ATP 
synthesis was initiated by the addition of ADP to a final concentration of 10mmot/L. 
Glutamate (10 mmol/L) + malate (2 mmol/L) or pyruvate (10 retool/L) + malate (2 mmol/L) 
were used as substrates for oxidative phosphorylation via complexes I, III and IV. 
Succinate (10mmol/L) (+2#g rotenone/mt to inhibit complex I) was used as a substrate 
for oxidative phosphorylation via complexes II, III and IV. 
Mitochondrial protein synthesis: After removing the normal culture medium, fibroblasts 
from exponentially growing cultures were rinsed twice with PBS and cultured in 
methionine-free DME containing 1mmol/L pyruvate and supplemented with 10% heat- 
inactivated fetal calf serum in a humidifed atmosphere of 10% CO 2 in air. After 1 h 
[35S]methionine (specific activity >960Ci/mmol) was added to a final concentration of
20 pCi/ml. Emetine labelling was used to suppress cytoplasmic protein synthesis. Emetine 
was added 10min before the addition of labelled methionine, to a final concentration f
100pg/ml. Equal amounts of labelled cells were solubilized by lauryl maltoside treatment. 
The samples were centrifuged and the supernatants were subjected to electrophoresis a
described (Sch~igger and Von Jagow 1987). The gels were dried under vacuum and 
labelled mitochondrial proteins were visualized by fluorography. The autoradiographic 
signals of the proteins were quantified on gels using a Phospho Imager. 
The activity of individual respiratory-chain enzymes was determined in freshly prepared 
cell lysates, obtained by treatment with lauryl maltoside, according to standard methods 
(Nijtmans et al 1995). 
PATIENTS 
Patient 1: This patient, described previously (Barth et al 1983) (pedigree no. V, 12), had 
neonatal lactic acidosis (up to 13.9mmol/L). On follow-up he had moderate muscle 
weakness, neutropenia, and dilated cardiomyopathy. He died from cardiac failure at 15 
months. Myocardial mitochondria were abnormal in structure. 
Patient 2: This patient was not related to patient 1. His maternal uncle died in infancy 
with a similar history,. The proband had failure to thrive (statural length on the 3rd centile, 
weight below the 3rd centile), dilated cardiomyopathy, and increased excretion of 3-methyl- 
glutaconic acid and 3-methylglutaric a id. He died, probably from cardiac failure, at 13 
months. Dilated cardiomyopathy was found at autopsy. 
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Substrate Patient 1 (n = 4) Patient 2 (n = 2) Control (n = 10) 
Glutamate/malate 18.1 (83%) 19.5 (88%) 22.0 (18.4-28.3) 
Pyruvate/malate 15.5 (75%) t7.6 (85%) 20.7 (16.4-26.4) 
Succinate (+rotenone) 11.2 (70%) 14.6 (91%) 15.9 (12.9 -18.6) 
~Activity expressed asnmol ATP/mg protein per min; % 'is percentage of normal mean 
Table 2 Mitoehondrial enzyme activities a 
Enzyme Patient I (n) Patient 2 (n) Control mean (range) (n) 
Complex I 3.0 (4) 3.4 (2) 3.6 (3.0-4.t) (11) 
Complex II 7.9 (4) 6.7 (2) 7.6 (5.6 -7.8) (11) 
Complex III 3.2 (4) 3.7 (4) 11.1 (10.2-14.9) (9) 
Complex tV b 0.31 (10) 0.42 (8) 0.58 (0.45-0.62) (53) 
Citrate synthase 87 (6) 75 (4) 78 (58-86) (53) 
"Activities expressed asnmol/mg protein per min 
bComplex IV: k (per min per rag) 
RESULTS 
Electrophoresis of polypeptides, labelled in the presence of emetine, showed no 
abnormalities in the mobility or the incorporation of radioactivity of mitochondrially 
encoded proteins. This suggests that the expression of mtDNA was normal in the 
fibroblasts from the patients. 
Results of respiratory-chain studies are given in Tables 1 and 2. 
CONCLUSIONS 
The ATP production from glutamate + malate, pyruvate +malate, or succinate (+ rotenone 
was lower than the mean values found in control fibroblasts in patient 1 and in the low- 
normal range in patient 2. Decreased activities of complex III (+30% of controls) and 
complex IV (+60% of controls) are in agreement with the previous studies in muscle. 
These findings provide evidence that respiratory-chain dysfunction is an essential 
component of Barth syndrome. Results further indicate that the gene product is essential 
for the function, formation or stability of both complex III and complex IV. Both complex 
III and complex IV contain subunits that are encoded by mtDNA. The results of emetine 
labelling make it unlikely that the gene is involved in the expression of mtDNA. We 
furthermore suspect hat 3-methylglutaconic a iduria in this syndrome represents an 
epiphenomenon which is as yet unexplained but hasbeen described so far in patients with 
separate mitochondrial disorders (Gibson et al 1995). 
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